To delineate the underlying mechanism whereby anti-SIRPα inhibited HCC progression in TME, we established a spontaneous tumor model and used anti-SIRPα mAb to treat the tumor (Fig. 5A). The gene discussed is SIRPA; the disease is neoplasm.